Secondary Prevention of Clostridioides Difficile Using Vancomycin | MicrobiomeTrials← Back to trialsNCT06979609
Secondary Prevention of Clostridioides Difficile Using Vancomycin
RecruitingPHASE2, PHASE3INTERVENTIONAL
Trial Details
Start: 2025-10-01Est. Completion: 2028-10-01
Enrollment target: 300 participants Locations- McGill University Health Centre, Montreal, Quebec, Canada
Other microbiome trials you might be interested in
Acute Leukemia in RemissionMyelodysplastic SyndromesMyeloproliferative SyndromeHodgkin LymphomaLymphoma, Non-HodgkinMyelomaChronic Lymphocytic Leukemia
The aim of this study is to assess the Fecal Microbiota Transplantation (FMT) efficacy in the prevention of allogeneic h…
Amiens, FranceEst. completion May 2030
Ulcerative Colitis (UC)Inflammatory Bowel Disease (IBD)Colitis
This Phase 2b randomized, double-blind, placebo-controlled, multicenter trial will evaluate the efficacy and safety of a…
Izmir, Turkey (Türkiye)Est. completion May 30, 2027
DysbiosisClostridium DifficilePet-Human BondingAntibiotic-Associated Colitis
Antimicrobial therapy can lead to disruption of the gut microbiome and infection with Clostridioides difficile, a diseas…
Philadelphia, United StatesEst. completion Sep 1, 2026